2024
Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears
Grossman M, Rankin D, Maloney M, Stanton R, Gable P, Stevens V, Ewing T, Saunders K, Kogut S, Nazarian E, Bhaurla S, Mephors J, Mongillo J, Stonehocker S, Prignano J, Valencia N, Charles A, McNamara K, Fritsch W, Ruelle S, Plucinski C, Sosa L, Ostrowsky B, Ham D, Walters M, Aguilar H, Alavi A, Balbuena R, Braut-Taormina J, Bruce H, Chambers W, Chen K, Clancy K, Cockrell M, Crayton K, Cyrus M, D'Angeli M, Diaz M, Dollete J, Eskenazi S, Fong L, Giardina R, Gogley J, Greendyke W, Hadman S, Houston H, Huck C, Istafanos P, Jean-Louis A, Jones D, Kratz M, Kwan T, La S, Lance S, Lasure M, Longo C, Machado M, McAllister G, McGarry S, McKay S, Miller D, Musk M, O'Yong K, Patel E, Pightling A, Rodriguez A, Rogers J, Romero H, Satyam M, Silverman M, Skolek G, Smith A, Stahl A, Torres L, Trivedi K, Wilmott N. Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears. Clinical Infectious Diseases 2024, 79: 6-14. PMID: 38315890, PMCID: PMC11259536, DOI: 10.1093/cid/ciae052.Peer-Reviewed Original ResearchCase-patientsCase-control studyDays of culture collectionCarbapenem-resistant Pseudomonas aeruginosaOver-the-counterArtificial tear useCarbapenemase-producing organismsDrug-resistant bacteriaCarbapenemase-producingSurveillance culturesPatient isolatesPreservative-freeClinical impactEye infectionsSpecimen sourceClinical culturesSequence typingIncreased oddsUnopened bottlesResistant bacteriaPost-acute care facilitiesCase statusBrand ABacterial contaminationCulture Collection
2023
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory Committee
2022
Epidemiologic and Clinical Features of Children and Adolescents Aged <18 Years with Monkeypox — United States, May 17–September 24, 2022
Hennessee I, Shelus V, McArdle C, Wolf M, Schatzman S, Carpenter A, Minhaj F, Petras J, Cash-Goldwasser S, Maloney M, Sosa L, Jones S, Mangla A, Harold R, Beverley J, Saunders K, Adams J, Stanek D, Feldpausch A, Pavlick J, Cahill M, O’Dell V, Kim M, Alarcón J, Finn L, Goss M, Duwell M, Crum D, Williams T, Hansen K, Heddy M, Mallory K, McDermott D, Cuadera M, Adler E, Lee E, Shinall A, Thomas C, Ricketts E, Koonce T, Rynk D, Cogswell K, McLafferty M, Perella D, Stockdale C, Dell B, Roskosky M, White S, Davis K, Milleron R, Mackey S, Barringer L, Bruce H, Barrett D, D’Angeli M, Kocharian A, Klos R, Dawson P, Ellington S, Mayer O, Godfred-Cato S, Labuda S, McCormick D, McCollum A, Rao A, Salzer J, Kimball A, Gold J, Group C, Group C, Group C, Berumen R, Cosentino G, Getabecha S, Glaser C, Grosgebauer K, Harriman K, Haw M, Kamali A, Kath C, Kim E, Lewis L, Sachdev D, Salas M, Stainken C, Wadford D, Peters P, Vaidya A, Group C, Adkins S, Baird ;, Barrios L, Beeson A, Blackburn D, Borah B, Click E, Davidson W, Galang R, Hufstetler K, Hutchins H, Kourtis A, Miller M, Morris S, Olsen E, Roth N, Sims E, Chatham-Stephens K. Epidemiologic and Clinical Features of Children and Adolescents Aged <18 Years with Monkeypox — United States, May 17–September 24, 2022. MMWR Morbidity And Mortality Weekly Report 2022, 71: 1407-1411. PMID: 36331124, PMCID: PMC9639439, DOI: 10.15585/mmwr.mm7144a4.Peer-Reviewed Original ResearchConceptsMale-to-male sexual contactPublic health priorityLt;18 yearsJurisdictional health departmentsSkin-to-skin contactChildren aged 0Adolescents aged <Intensive care unit (ICU)-level careUnited StatesHealth priorityNon-HispanicHealth departmentsPrevention informationMonkeypox virusAged 0Prevent additional infectionsRisk factorsCareAdolescentsClinical featuresMonkeypox vaccineChildrenLt;18Monkeypox casesSexual contactSARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022
Baker J, Nakayama J, O’Hegarty M, McGowan A, Teran R, Bart S, Mosack K, Roberts N, Campos B, Paegle A, McGee J, Herrera R, English K, Barrios C, Davis A, Roloff C, Sosa L, Brockmeyer J, Page L, Bauer A, Weiner J, Khubbar M, Bhattacharyya S, Kirking H, Tate J. SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022. MMWR Morbidity And Mortality Weekly Report 2022, 71: 341-346. PMID: 35238860, PMCID: PMC8893332, DOI: 10.15585/mmwr.mm7109e1.Peer-Reviewed Original ResearchConceptsHousehold contactsIndex patientCOVID-19 primary seriesSARS-CoV-2Prevention strategiesCOVID-19 booster doseEffectiveness of prevention strategiesBooster dosePrimary seriesOmicron infectionPatientsOmicron transmissionHousehold transmissionVariant transmissionInfected personsHousehold settingsCOVID-19Cases of COVID-19InfectionOmicron
2020
Treatment Guidelines for Active Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis, and Latent Tuberculosis Infection
Sosa L, Friedman L. Treatment Guidelines for Active Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis, and Latent Tuberculosis Infection. 2020, 393-398. DOI: 10.1201/9781351249980-20.Peer-Reviewed Original ResearchExtensively drug-resistant tuberculosisInjectable agentsThree-drug regimensResistance to isoniazidMultidrug-resistant tuberculosisUnited States Food and Drug AdministrationLatent tuberculosis infectionDrug-resistant tuberculosisStates Food and Drug AdministrationDrug-sensitive tuberculosisFood and Drug AdministrationPulmonary tuberculosisSensitive to isoniazidDrug susceptibilityResistant TBTuberculosis infectionTreatment guidelinesDrug AdministrationRifampinWorld Health OrganizationTuberculosisIsoniazidRegimensMonthsTreatment
2017
Notes from the Field: Powassan Virus Disease in an Infant — Connecticut, 2016
Tutolo J, Staples J, Sosa L, Bennett N. Notes from the Field: Powassan Virus Disease in an Infant — Connecticut, 2016. MMWR Morbidity And Mortality Weekly Report 2017, 66: 408-409. PMID: 28426641, PMCID: PMC5687186, DOI: 10.15585/mmwr.mm6615a3.Peer-Reviewed Original Research